What is Allakos?
Allakos Inc. is a clinical-stage biotechnology firm headquartered in San Carlos, California, dedicated to the development of novel therapeutics that target immunomodulatory receptors on immune effector cells. The company's primary focus lies in addressing unmet medical needs within the allergy, inflammatory, and proliferative disease landscapes. Its lead product candidate, AK006, is currently undergoing rigorous clinical evaluation, specifically targeting chronic spontaneous urticaria and other related indications. By focusing on the underlying mechanisms of immune-mediated conditions, Allakos occupies a specialized niche in the biopharmaceutical sector, aiming to transform treatment paradigms for patients suffering from chronic, debilitating conditions.
How much funding has Allakos raised?
Allakos has raised a total of $276.4M across 3 funding rounds:
Series A
$42M
Series B
$100M
Stock Offering
$134.4M
Series A (2014): $42M with participation from Alta Partners, RiverVest, and Novo Ventures
Series B (2017): $100M led by Rock Springs Capital, LifeSci Venture Partners, Redmile Group, 3x5 Partners, Roche, RiverVest Venture Partners, New Enterprise Associates, Samsara BioCapital, Alta Partners, and Partner Fund Management
Stock Issuance/Offering (2018): $134.4M, investors not publicly disclosed
Key Investors in Allakos
Alta Partners
Alta Partners is a prominent venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies since 1996.
Novo Ventures
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term life science investments.
New Enterprise Associates
Established in 1977, New Enterprise Associates is a global venture capital firm focused on helping entrepreneurs build transformative businesses across various sectors.
What's next for Allakos?
With the recent influx of capital, Allakos is poised to advance its clinical pipeline, particularly the Phase I trials for AK006. The strategic focus will likely shift toward optimizing trial design, scaling manufacturing capabilities, and preparing for potential regulatory milestones. As the company matures, the emphasis will remain on validating the efficacy and safety profiles of its therapeutic candidates to ensure long-term commercial viability. Investors will be closely monitoring the data readouts from ongoing studies, as these results will serve as the primary catalyst for future valuation growth and potential strategic partnerships within the global pharmaceutical ecosystem.
See full Allakos company page
